FDA accelerated approval covers zanidatamab-hrii for HER2-positive biliary tract cancer
The approval applies to previously treated patients with unresectable or metastatic disease whose tumors are HER2-positive by IHC 3+ testing.
FDA
20 stories
The approval applies to previously treated patients with unresectable or metastatic disease whose tumors are HER2-positive by IHC 3+ testing.
FDA
Zymeworks reported third-quarter 2026 results, raised full-year revenue and EBITDA guidance, and detailed a new Roche collaboration on ZW209 pending antitrust clearance.
SEC filing
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
The company launched Ziihera in first-line gastric cancer, closed its Actio acquisition, and lifted full-year revenue guidance to $4.775-$4.85 billion.
SEC filing
The company said the charge from its completed Actio acquisition will cut roughly $11.00 from both GAAP and non-GAAP EPS in the third quarter of 2026.
SEC filing
Samantha Pearce told the company on October 6, 2026 that she will step down as Chief Commercial Officer no later than June 30, 2027, or sooner if a successor is named.
SEC filing
Hamill, who led Gilead's worldwide commercial operations, joins Entera's board effective December 1, 2026, replacing departing director Yonatan Malca.
SEC filing
The phase II study combining DA-EPOCH chemotherapy with Jazz Pharmaceuticals' recombinant Erwinia asparaginase in newly diagnosed adult leukemia patients stays halted, per a registry update posted September 29, 2026.
SEC filing, ClinicalTrials.gov (2)
The appointment, effective October 1, 2026, follows Celcuity's first FDA approval and the September 30 US launch of REVTORPYK for advanced breast cancer.
SEC filing (2)
The genetic medicines company named Sebulsky a Class I director effective September 23, 2026, with a term running until the 2028 annual meeting.
SEC filing
Jazz Lux amended its credit agreement on September 23, 2026, cutting the interest margin by 50 basis points and pushing the maturity date out five years to 2033.
SEC filing
The former FDA official and regulatory consultant joins as a Class II director effective September 15, 2026.
SEC filing
The $820 million deal brings Jazz an oral KCNT1 inhibitor for KCNT1-related epilepsy that has shown seizure reductions in an early pediatric trial.
SEC filing